Maxigra Max

Sildenafil, the active ingredient in Maxigra Max, is a phosphodiesterase type 5 (PDE5) inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of erectile dysfunction in adult males, improving the ability to achieve and maintain an erection during sexual stimulation.

GNH USA supplies Maxigra Max as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements across EU and global markets continually.

Sildenafil is a phosphodiesterase type 5 inhibitor used to manage conditions related to impaired blood flow.

- Erectile dysfunction: improves ability to achieve and maintain an erection. - Pulmonary arterial hypertension: lowers pulmonary arterial pressure and enhances exercise tolerance. - Erectile dysfunction associated with diabetes: facilitates erection in men with diabetic‑related vascular impairment.

Sildenafil may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate pain often resolving without treatment. - Flushing: warmth and redness of the face or upper body. - Dyspepsia: indigestion or upset stomach. - Nasal congestion: blocked or runny nose. - Visual disturbances: blurred vision or color tinge changes. - Back pain: muscle aches, typically after prolonged use.

Serious or Rare Side Effects: - Priapism: prolonged erection lasting more than four hours, requiring urgent medical attention. - Sudden vision loss: non‑arteritic anterior ischemic optic neuropathy. - Sudden hearing loss: abrupt decrease or loss of hearing. - Cardiovascular events: chest pain, arrhythmia, or myocardial infarction in high‑risk patients.

Before initiating therapy, patients should be evaluated for underlying health conditions and potential risks.

- Medical evaluation: assess cardiovascular status and suitability for sexual activity. - Nitrate therapy: contraindicated due to risk of severe hypotension. - Retinitis pigmentosa: avoid use as it may worsen visual symptoms. - Alcohol consumption: limit intake as it can increase side‑effect frequency. - Renal or hepatic impairment: consider dose adjustment and monitor response. - Store at ambient temperature: keep below 25 °C, in the original packaging, and protect from moisture.

Sildenafil can interact with several medicines, altering its safety or effectiveness.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin): may cause life‑threatening hypotension. - Guanylate cyclase stimulators (e.g., riociguat): risk of excessive blood pressure drop. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase sildenafil plasma levels.

Moderate Interactions (Monitor Closely): - Alpha‑blockers (e.g., doxazosin): may enhance hypotensive effect. - Antihypertensives (e.g., beta‑blockers): monitor blood pressure for additive lowering. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce sildenafil efficacy.